Below are the most recent publications written about "Drug Resistance, Viral" by people in Profiles.
-
Zhang S, Holmes AP, Dick A, Rashad AA, Enr?quez Rodr?guez L, Canziani GA, Root MJ, Chaiken IM. Altered Env conformational dynamics as a mechanism of resistance to peptide-triazole HIV-1 inactivators. Retrovirology. 2021 10 09; 18(1):31.
-
James CW, Szabo S, Kahal D, Goldstein ND. The effect of multivitamins and polyvalent cations on virologic suppression with integrase strand transfer inhibitors. AIDS. 2020 03 01; 34(3):487-489.
-
Smith AR, Weinstock MT, Siglin AE, Whitby FG, Francis JN, Hill CP, Eckert DM, Root MJ, Kay MS. Characterization of resistance to a potent D-peptide HIV entry inhibitor. Retrovirology. 2019 10 22; 16(1):28.
-
Zhang Y, Zmasek C, Sun G, Larsen CN, Scheuermann RH. Hepatitis C Virus Database and Bioinformatics Analysis Tools in the Virus Pathogen Resource (ViPR). Methods Mol Biol. 2019; 1911:47-69.
-
Hassibi A, Manickam A, Singh R, Bolouki S, Sinha R, Jirage KB, McDermott MW, Hassibi B, Vikalo H, Mazarei G, Pei L, Bousse L, Miller M, Heshami M, Savage MP, Taylor MT, Gamini N, Wood N, Mantina P, Grogan P, Kuimelis P, Savalia P, Conradson S, Li Y, Meyer RB, Ku E, Ebert J, Pinsky BA, Dolganov G, Van T, Johnson KA, Naraghi-Arani P, Kuimelis RG, Schoolnik G. Multiplexed identification, quantification and genotyping of infectious agents using a semiconductor biochip. Nat Biotechnol. 2018 09; 36(8):738-745.
-
Diphoko T, Gaseitsiwe S, Kasvosve I, Moyo S, Okatch H, Musonda R, Wainberg M, Makhema J, Marlink R, Novitsky V, Essex M. Prevalence of Rilpivirine and Etravirine Resistance Mutations in HIV-1 Subtype C-Infected Patients Failing Nevirapine or Efavirenz-Based Combination Antiretroviral Therapy in Botswana. AIDS Res Hum Retroviruses. 2018 08; 34(8):667-671.
-
Hodder S, Squires K, Kityo C, Hagins D, Avihingsanon A, Kido A, Jiang S, Kulkarni R, Cheng A, Cao H. Brief Report: Efficacy and Safety of Switching to Coformulated Elvitegravir, Cobicistat, Emtricitabine, and Tenofovir Alafenamide (E/C/F/TAF) in Virologically Suppressed Women. J Acquir Immune Defic Syndr. 2018 06 01; 78(2):209-213.
-
Yamani LN, Yano Y, Utsumi T, Wasityastuti W, Rinonce HT, Widasari DI, Lusida MI, Hayashi Y. Profile of Mutations in the Reverse Transcriptase and Overlapping Surface Genes of Hepatitis B Virus (HBV) in Treatment-Naïve Indonesian HBV Carriers. Jpn J Infect Dis. 2017 Nov 22; 70(6):647-655.
-
Mo H, Hedskog C, Lawitz E, Brainard DM, Yang J, Delaney W, Worth A, Miller MD. Antiviral response and resistance analysis of treatment-na?ve HCV infected patients receiving multiple doses of the NS3 protease inhibitor GS-9256. Antiviral Res. 2017 04; 140:151-157.
-
Yang H, Yang C, Wang Y, Rhodes G, Robinson M, Cheng G, Qi X, Mo H, Tian Y, Pakdaman R, Sheng XC, Kim CU, Delaney WE. Preclinical characterization of the novel HCV NS3 protease inhibitor GS-9256. Antivir Ther. 2017; 22(5):413-420.